Delcath Systems (NASDAQ:DCTH) Stock Price Up 1.7%

Delcath Systems, Inc. (NASDAQ:DCTH) shares rose 1.7% during mid-day trading on Wednesday . The stock traded as high as $8.89 and last traded at $8.84. Approximately 173,348 shares traded hands during mid-day trading, a decline of 29% from the average daily volume of 243,169 shares. The stock had previously closed at $8.69.

Wall Street Analysts Forecast Growth

DCTH has been the subject of several recent analyst reports. Craig Hallum initiated coverage on Delcath Systems in a research report on Friday, June 28th. They issued a “buy” rating and a $18.00 price target for the company. HC Wainwright lifted their price target on Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Finally, Stephens started coverage on Delcath Systems in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.83.

Delcath Systems Stock Performance

The stock has a 50-day simple moving average of $7.76 and a two-hundred day simple moving average of $5.78. The firm has a market cap of $241.77 million, a PE ratio of -3.28 and a beta of 0.64.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.70 million. As a group, sell-side analysts anticipate that Delcath Systems, Inc. will post -1.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently made changes to their positions in the business. Levin Capital Strategies L.P. increased its position in shares of Delcath Systems by 22.5% during the 4th quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock valued at $204,000 after purchasing an additional 9,000 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Delcath Systems during the 4th quarter valued at about $962,000. Legato Capital Management LLC purchased a new stake in shares of Delcath Systems during the 2nd quarter valued at about $966,000. Worth Venture Partners LLC purchased a new stake in shares of Delcath Systems during the 4th quarter valued at about $1,224,000. Finally, Vanguard Group Inc. grew its stake in shares of Delcath Systems by 31.0% during the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after acquiring an additional 161,678 shares during the period. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.